News

Matrixx has said that it is in the process of formally notifying retailers, wholesalers and distributors nationwide, of its recall of all Zicam Cold Remedy Nasal Gel and

Acusphere has cancelled Cephalon’s $15 million Senior Secured Convertible Note. It has amended March and November 2008 License Agreements with Cephalon, for the oncology applications of Acusphere’s Hydrophobic

Atox Bio and Fast-Track Drugs & Biologics have signed R&D collaboration agreement for the development of Atox Bio’s novel mechanism-based immunomodulator peptide, AB103. It is intended for the

ImmunoCellular (IMUC) has signed an agreement with Formatech for the manufacture of IMUC’s cancer stem cell vaccine, ICT-121, for an upcoming clinical trial. ICT-121 is a product candidate

Neuralstem has entered into a sponsored research agreement with the China Medical University & Hospital of Taiwan, to prepare for a human clinical trial (using Neuralstem’s human spinal

Spherix has announced positive preliminary results from phase-II clinical trial of Naturlose (D-tagatose), in the treatment and management of Type 2 diabetes. The phase-II trial was single-blind, prospective,

Glenmark’s Melogliptin has recently completed 12 weeks phase-IIb clinical trial in 494 patients with type 2 diabetes mellitus, and is now ready to initiate phase III trials. In

GlaxoSmithKline (GSK) has received a complete response letter from FDA, related to the application for casopitant (Rezonic). The company is reviewing it and will slot in with the

PriCara, a division of Ortho-McNeil-Janssen Pharmaceuticals, has announced the launch of Nucynta (tapentadol) CII immediate release tablets. Nucynta works by binding with mu-opioid receptors and inhibiting norepinephrine re-uptake.